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Figure 1A. Treatment modality in newly diagnosed patients with hepatocellular 
carcinoma from 1996 to 2005 according to data from the 14th to 18th Nationwide 
Follow-up Survey of Primary Liver Cancer in Japan (percentages for 1996–1997 and 
1998–1999 were calculated from the original Japanese version of the data).[3, 5-8] 
TACE = transcatheter arterial embolization. 
Figure 1B. Method of chemotherapy administration in newly diagnosed patients with 
hepatocellular carcinoma from 1996 to 2005 according to data from the 14th to the 
18th Nationwide Follow-up Survey of Primary Liver Cancer in Japan (percentages for 
1998–1999, 2000–2001 and 2002–2003 were calculated from the original Japanese 
version of the data).[3, 5-8] HAIC = hepatic arterial infusion chemotherapy. 
Figure 1C. Response rates to chemotherapy for newly diagnosed patients with 
hepatocellular carcinoma from 1996 to 2005 according to data from the 14th to the 
18th Nationwide Follow-up Survey of Primary Liver Cancer in Japan.[3, 5-8] 
Figure 2. Computed tomography images (a) after sorafenib therapy but before hepatic 
artery infusion chemotherapy and (b) after sorafenib treatment followed sequentially 
by hepatic artery infusion chemotherapy comprising 5-fluorouracil, cisplatin, and 




Hepatic artery infusion chemotherapy (HAIC) allows long-term administration of 
cytotoxic drugs to the liver. In Japan, HAIC has traditionally been used to treat 
patients with advanced hepatocellular carcinoma (HCC) with vascular invasion and/or 
multiple intrahepatic lesions. The most common chemotherapy drugs used for HAIC 
in Japan are 5-fluorouracil and cisplatin. 
Although HAIC is associated with a high rate of response in some studies, it is not 
associated with a survival benefit. Furthermore, HAIC is associated with 
complications that are not observed with systemic chemotherapy, including peptic 
ulcer, arterial occlusion and port infection. 
Recently, a molecular targeted agent, sorafenib, became the standard therapy for 
advanced HCC on the basis of data from two randomized controlled trials. For this 
reason, the position of HAIC in the treatment of advanced HCC in Japan is under 
discussion. Clinical trials must be undertaken to establish standardized protocols and 
regimens for HAIC, and to determine the efficacy of HAIC in comparison with other 
therapies for HCC. Without evidence from such trials, HAIC may not find an 
established role in the treatment of HCC, and may even fall out of use. 
Recent evidence suggests that HAIC may be useful in combination with molecular 
targeted therapy; this is currently being investigated in a number of clinical trials. 
<<Dear author, Reviewer 1 said: My understanding is that outside of Japan, TACE and 
hepatic arterial infusion are used as combination but just one of these procedures is used in 
Japan. It has been suggested that  the merit of combination therapy with TACE and hepatic 
arterial infusion could be suggested to Japanese doctors. Can you comment on this in your 
paper/add this to the section on Future Prospects of TACE? 
Our reply would be that HAIC for HCC is primarily used in Japan and some Asian countries, 
hence the Reviewer’s proposed comment is not relvant for this paper. Please let us know 
what you think. Thank you.>> 
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Introduction 
Conventional chemotherapy for advanced hepatocellular carcinoma (HCC) comprises 
systemic chemotherapy (administered intravenously or orally) or hepatic arterial 
infusion chemotherapy (HAIC). Both systemic chemotherapy and HAIC have been 
shown to be effective in patients with advanced HCC in Japan.[1] 
HAIC allows long-term administration of cytotoxic drugs to the liver through the use 
of an indwelling catheter-port system. Compared with systemic chemotherapy, HAIC 
delivers a higher local drug concentration directly to liver tumours and is associated 
with fewer significant systemic side effects.[2] In the past, catheters were placed 
surgically under general anaesthesia; however, owing to recent advances in 
interventional radiological techniques, it is now possible to insert catheter-port 
systems percutaneously under local anaesthesia.[2] 
In Japan, HCC is a common malignancy,[3] and is one of the leading causes of cancer 
mortality.[4] HAIC is a treatment for HCC that is used primarily in Japan and some 
other Asian countries, including Korea. Data from some studies indicate that HAIC is 
associated with a high response rate; however, treatment response has not been 
consistent across studies and there is little evidence of a survival benefit with HAIC. 
Recently, molecular targeted therapy became a new field of cancer chemotherapy for 
patients with HCC. The introduction of such agents has meant that the role of HAIC 
in patients with advanced HCC is under discussion. The current review discusses the 
current status of HAIC for the treatment of HCC in Japan and the role that this form 
of treatment may play in the future. The contents of this  review are based on a 
Medline literature search (from    20xx to 20yy) using the following search terms: 
<<Author please list search terms>>. 
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Current Status of Chemotherapy for Hepatocellular Carcinoma in 
Japan 
According to data from the 14th to the 18th Nationwide Follow-up Survey of Primary 
Liver Cancer conducted in Japan between 1996 and 2005,[3, 5-8] chemotherapy was 
used as initial therapy in 3.4% of newly diagnosed patients with HCC in 1996–1997, 
increasing to 5.5% of patients in 2004–2005 (figure 1A). Of those patients who were 
initially treated with chemotherapy, HAIC was the most common administration 
method (figure 1B); between 2000 and 2005, the proportion of chemotherapy patients 
who received treatment in the form of HAIC was approximately 90%.[3, 5-8] In the 
same time period, the proportion of patients with HCC who had a complete response 
to chemotherapy (assessed according to various criteria) ranged from 13.5%–19.9%. 
During the same time period, 25.5%–30.2% of patients had a partial response to 
chemotherapy (figure 1C).[3, 5-8] 
Guideline Recommendations for the Use of Hepatic Artery Infusion 
Chemotherapy in Patients with Hepatocellular Carcinoma 
Japan 
The Clinical Practice Guidelines for Hepatocellular Carcinoma (J-HCC) were the first 
evidence-based guidelines for the treatment of HCC in Japan. The J-HCC guidelines 
were compiled by an expert panel supported by the Japanese Ministry of Health, 
Labour, and Welfare, and encompass the prevention, diagnosis, surveillance, and 
treatment of HCC. They were first developed in 2005, and were subsequently revised 
in 2009. The most recent version of the J-HCC guidelines recommend the use of 
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HAIC or transcatheter arterial embolization (TACE) in patients with multifocal HCC 
(four or more tumours) who have Child-Pugh class A or B liver disease. HAIC (or 
hepatectomy or TACE) is also recommended for those patients with Child-Pugh class 
A liver disease accompanied by vascular invasion.[9] An English translation of the 
guidelines is available at the following URL: 
http://www.jsh.or.jp/english/examination.html. 
Other Countries 
Although HAIC is recommended for the treatment of HCC in certain situations in 
Japan, as described previously, a number of international practice guidelines do not 
endorse the use of HAIC in patients with HCC. The Barcelona-Clinic Liver Cancer 
staging classification and treatment schedule[10] does not include HAIC in its list of 
treatment options for HCC, while the American Association for Study of Liver 
Disease practice guidelines[11] state that “systemic or selective intra-arterial 
chemotherapy is not recommended and should not be used as standard of care”. 
Although the 2010 version of the practice guidelines for hepatobiliary cancers 
developed by the National Comprehensive Cancer Network recommends the use of 
systemic single-agent or multiple-agent chemotherapy or intra-arterial chemotherapy 
in patients with unresectable HCC, this is restricted to those patients participating in a 
clinical trial.[12] 
Hepatic Arterial Infusion Chemotherapy Versus Systemic 
Chemotherapy 
There are almost no well-designed, controlled studies that have directly compared 
systemic chemotherapy and HAIC for the treatment of HCC, and there are insufficient 
data to show that one treatment is better than the other. Indeed, in the 2009 version of 
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the J-HCC guidelines it is noted that there is “no sufficient scientific evidence that 
hepatic arterial infusion chemotherapy is more beneficial than systemic 
chemotherapy”.[13] In developing the guidelines, an analysis of response rates in trials 
that investigated each type of chemotherapy in 30 or more patients was undertaken. 
Data from these trials showed that the rate of response was 22%–71% with HAIC 
compared with 0%–28% with single-agent systemic chemotherapy and 2.5%–39% 
with multiple-agent systemic chemotherapy; the median survival time (MST) with 
these treatment modalities was 4.4–32.4, 1.9–13.7, and 3.0–30.9 months, 
respectively.[13] These data suggested that HAIC was more beneficial than systemic 
chemotherapy; however, there was great variability in the outcomes assessed, most 
likely as a result of the different sample sizes and selection criteria of the individual 
studies. The final recommendation that HAIC was no better than systemic 
chemotherapy was based on the results of a randomized trial that directly compared 
the effects of doxorubicin administered as HAIC or as systemic chemotherapy in 64 
patients with unresectable HCC.[14] Although the proportion of patients who 
experienced a complete response or a partial response was numerically higher in the 
HAIC group versus the systemic chemotherapy group (60.0% vs. 44.1% of patients), 
MST was not significantly different in the two treatment groups (7.0 vs. 6.5 months). 
Standard Hepatic Artery Infusion Chemotherapy Protocols 
In contrast to what has been observed for other malignant tumours, there are relatively 
few large-scale, randomized controlled studies that have investigated the efficacy of 
chemotherapy for the treatment of HCC.[13] As such, according to the expert panel 
that developed the 2009 J-HCC guidelines, there is no established standard 
chemotherapy protocol for the treatment of advanced HCC.[13] 
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Within Japan, 5-fluorouracil (5-FU) and cisplatin (CDDP) are the most common 
chemotherapy drugs used for HAIC; these agents account for more than 50% of those 
used for HAIC.[15-18]  HAIC may involve multiple agents or a single agent. In Japan, 
representative HAIC protocols include 5-FU plus CDDP (primarily at low doses), 
interferon (IFN) plus 5-FU, and CDDP alone; however, the optimal regimens of these 
protocols have not been established. 
Cisplatin plus 5-Fluorouracil 
HAIC with low-dose 5-FU plus CDDP is commonly used in patients with advanced 
HCC, but requires careful monitoring of haematological function.[19] In studies 
involving 16–97 patients,[19-30] HAIC with 5-FU plus CDDP was associated with a 
complete or partial response in 8%–71% of patients and an MST of 6.0–15.9 months. 
There was much variation in the dose of 5-FU and CDDP administered in these 
studies, as well as variation in the timing and duration of the two treatments. To 
establish the optimum regimen of HAIC with 5-FU plus CDDP, the dose, infusion 
time, and dosing interval of 5-FU as well as the dose, infusion time, and dosing 
duration of CDDP should be standardized in future. Further research should also 
focus on the combination of 5-FU and CDDP with leucovorin/isovorin[31, 32] and 
lipiodol[33]; preliminary data from small-scale studies show that these combinations 
may be suitable for patients with advanced HCC. 
Interferon plus 5-Fluorouracil 
Combination chemotherapy with IFN and 5-FU has been shown to be effective in 
patients with HCC. In studies involving 10–116 patients with HCC,[34-42] HAIC with 
IFN plus 5-FU was associated with a response rate of 14%–85% and an MST of 6.5–
31.8 months. In several of the studies, 5-FU was administered as a continuous 
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infusion at a dose of approximately 500 mg/day, whereas the type and the dose of IFN 
varied. Further research should focus on the optimum IFN species (IFNα-2b, natural 
IFNα, or pegylated IFN) to use, the patient groups for which HAIC with IFN plus 5-
FU is indicated, and the rationale for combining IFN with a cytotoxic drug. In 
addition, research should assess the feasibility of combining IFN, 5-FU and CDDP; 
although data suggest that HAIC with IFN, 5-FU and CDDP may be beneficial in 
patients with HCC,[43] no standard regimen for this combination has been established. 
Single-Agent Cisplatin 
In studies involving 10–80 patients,[44-48] HAIC with CDDP was associated with 
response rates of 14–42% and an MST of 2.6–10.7 months (mean survival time of 
19.7 months in one study). Although the first CDDP formulation (fine powder) 
intended for HAIC (IA call®; Nippon Kayaku, Tokyo, Japan) was approved and 
marketed in Japan in 2004, the optimum formulation, dose, and dosing interval of this 
drug has yet to be determined. Further research into the efficacy of CDDP in 
combination with lipiodol should be undertaken; data from a phase I/II study 
conducted in patients with unresectable HCC has shown this combination to be 
effective and well tolerated.[49] 
Case Studies of Patients Treated with Hepatic Artery Infusion 
Chemotherapy 
A number of patients with advanced HCC have shown a dramatic response to several 
cycles of HAIC. Such patients were treated with curative therapy, including hepatic 
resection and radiofrequency ablation, following treatment with HAIC and went on to 
survive for more than five years. Two such case studies are described here. Despite 
that the patients showed a dramatic response to HAIC, few prospective studies have 
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evaluated the survival of HCC patients following treatment with HAIC. 
A 70-year-old male with type C liver cirrhosis (Child-Pugh score 7/class B) presented 
to the clinic. The patient had multifocal HCC (major lesion, 11 cm) with tumour 
thrombus in the right portal branch (VP3) and leg veins, but had no lymph node or 
distant metastases. Nine cycles of HAIC with IFN plus 5-FU were administered from 
November 2004, resulting in a 48% reduction in tumour size (partial response). Two 
subsequent cycles of HAIC with IFN, 5-FU, and CDDP were given but further 
tumour regression was not observed. In October 2006, the patient underwent hepatic 
resection as salvage therapy. As of March 2010, the patient was alive and recurrence 
free. Owing to the effect of salvage therapy, the survival time from the start of HAIC 
was more than 65 months. This experience reemphasizes the importance of salvage 
therapy. 
A 60-year-old male with type B liver cirrhosis (Child-Pugh score 8/class B) with 
multifocal HCC (major lesion, 5.3 cm), tumour thrombus in the right to left portal 
branches (VP4), and no lymph node or distant metastases presented for treatment. 
Five cycles of HAIC with IFN plus 5-FU were administered from December 2004 
onwards. A 47% decrease in tumour size was observed, as was regression of portal 
invasion. Suspected residual tumours were treated by radiofrequency ablation. The 
patient was subsequently treated with three cycles of radio frequency ablation for 
recurrence in segment 5 and has survived for more than five years. The survival time 
from the start of HAIC was more than 64 months. 
Complications of Hepatic Artery Infusion Chemotherapy 
HAIC requires the precise placement of the catheter tip so as to optimize hepatic 
chemoinfusion and to reduce extrahepatic cytotoxic side effects.[2] To this end, 
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specific skills for arterial catheterization are required. 
Because HAIC requires the implantation of a catheter-port system, it is considered 
invasive for patients. Furthermore, the process is associated with complications that 
are not observed with systemic chemotherapy, including bruising and formation of 
hematomas at the puncture and port pocket site. Additional complications may 
include dislocation of the catheter, thrombotic occlusion of the catheter and/or the 
hepatic artery, and stroke.[2] Development of abdominal pain following HAIC has also 
been observed by the author. Further investigation with gastric endoscopy in the 
affected patient showed a red lesion with an ulcerated centre in the vestibule, 
suggesting that the cytotoxic drug used for HAIC may have leaked into the 
gastrointestinal tract causing a peptic ulcer. 
Vascular complications of HAIC, including hepatic arterial vasculitis and occlusion, 
port infection, and catheter occlusion, may also occasionally occur. 
Hepatic Artery Infusion Chemotherapy Compared with Sorafenib 
Within Japan, HAIC is considered an unsuitable treatment option in patients with 
HCC with multiple intrahepatic nodules or HCC with portal invasion, lymph node 
involvement, and/or distant metastasis. Thus, HAIC is restricted to patients with HCC 
with extensive vascular invasion (VP3/4), HCC with very extensive portal invasion 
(VP4) and a massive intrahepatic lesion, or bilobar multifocal HCC with multiple 
intrahepatic lesions that are unresponsive to TACE. 
Recently, the role of HAIC for the treatment of advanced HCC in Japan has been 
revisited. This has been prompted by the publication of the results of two randomized, 
controlled, phase III  trials, which showed that the molecular targeted therapy, 
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sorafenib, was effective for the treatment of advanced HCC.[50, 51] These results led to 
sorafenib being preferentially indicated for the treatment of HCC with distant 
metastasis, multiple intrahepatic lesions, and/or vascular invasion, thereby, in the 
author’s opinion, reducing the role of HAIC in the treatment of HCC in Japan. If 
HAIC is to be considered a recognized treatment for HCC and not fall out of use, 
clinical studies that establish its efficacy in comparison with other therapies for HCC, 
as well as the optimal treatment protocol and regimen, should be conducted. 
Sorafenib was approved for use in Japan in May 2009.[52] In the absence of direct 
comparative data, a comparison of HAIC and sorafenib with regard to regional usage, 
advantages, disadvantages, tumour response rate, patient survival and cost of 
treatment is provided in table I. 
Sequential Therapy with Sorafenib and Hepatic Artery Infusion 
Chemotherapy 
It is the author’s experience that sequential therapy with sorafenib then HAIC may be 
effective. Treatment with sorafenib then HAIC was trialled in a 70-year-old male with 
type C liver cirrhosis who was referred to the author’s clinic in May 2009, one month 
after a diagnosis of HCC. The patient was an alcoholic with a family history of HCC. 
Computed tomography (CT) and CT hepatic arteriography showed bilobar multifocal 
HCC with multiple intrahepatic lesions. At baseline, the patient had Child-Pugh 
class A liver disease. Following treatment with sorafenib 800 mg/day, the patient 
experienced fever, rash and back pain. The back pain was the result of bone 
metastasis that was not present at the initial diagnosis; radiotherapy was directed 
toward the bone metastasis. Response to sorafenib was judged as progressive disease. 
Follwoing two cycles of HAIC with IFN, 5-FU, and CDDP, the liver tumour size was 
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reduced by 34% (partial response according to version 1 of the Response Evaluation 
Criteria In Solid Tumors [53]) (Figure 2). The patient remains alive 13 months after the 
initiation of sorafenib therapy. This case study is intriguing as it highlights the 
possibility that prior treatment with sorafenib may render tumour cells more sensitive 
to cytotoxic effects. Further experience with HAIC in other patients unresponsive to 
sorafenib also suggests prior treatment with sorafenib may enhance tumour response 
to cytotoxic drugs. 
Concurrent Therapy with Sorafenib and Hepatic Artery Infusion 
Chemotherapy 
Concurrent treatment with HAIC and sorafenib is now under investigation in several 
clinical trials in Japan, including the Phase III SILIUS trial (ClinicalTrials.gov 
identifier, NCT01214343; UMIN clinical trials registry identifier, UMIN000004315). 
This randomized, open-label trial will compare the efficacy of 28-day cycles of 
sorafenib alone (400mg bid) and sorafenib plus HAIC comprising low-dose CDDP 
(20 mg/m2 on days 1 and 8), and 5-FU (330 mg/m2 administered continuously on days 
1–5 and 8–12) in 190 patients with advanced HCC aged >20 years. Treatment will be 
continued until radiographic or symptomatic progression, or development of 
unacceptable toxicity. The primary outcome measure is overall survival, but time to 
disease progression, progression-free survival, change in tumour markers, and 
biomarkers predicting efficacy will also be evaluated. This trial commenced in 
October 2010; as of February 2012, recruitment was ongoing and completion of the 
study and primary outcome measure data collection was planned for September 2013. 
The safety of sorafenib and CDDP HAIC has recently been investigated in a Phase I, 
non-randomized, dose-finding clinical trial in patients with advanced HCC (UMIN 
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clinical trials registry identifier, UMIN000001496). Twenty-one patients aged 
between 20 and 79 years received sorafenib 400 mg twice daily combined with six 
courses of CDDP administered every 4–6 weeks. Results from this study are 
anticipated as the date of first enrolment was December 2008 and as of January 2012, 
study recruitment had ceased. 
Conclusions 
Traditionally, HAIC has been used in Japan to treat HCC with vascular invasion 
and/or multiple intrahepatic lesions. Although HAIC has been associated with high 
response rates in some studies, the outcome of therapy has not been consistent. 
Furthermore, there is little evidence of a survival benefit with HAIC. Sorafenib, a 
molecular targeted drug, has been established as the new standard of care in patients 
with HCC, based upon the results of two randomized, controlled clinical trials. As 
such, the position of HAIC for the treatment of advanced HCC is under discussion. If 
HAIC is to be considered a recognized treatment for HCC, clinical studies that 
establish its efficacy in comparison with other therapies for HCC as well as the 
optimal treatment protocol and regimen must be undertaken. In the absence of such 
data, HAIC may fall out of use. Recently, it has emerged that HAIC may be useful 
when combined (either sequentially or concurrently) with sorafenib. The combination 
of HAIC with molecular targeted therapy is currently being investigated in a number 
of clinical trials, the results of which are awaited with interest. 
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Tables 
Table I.. Key characteristics of hepatic artery infusion chemotherapy (HAIC) and 
sorafenib for the treatment of hepatocellular carcinoma. 
 HAIC Sorafenib 
Primary country of use Japan and Korea USA, Europe 
Advantages Substantial tumour shrinkage 
possible 
Regression of tumour thrombi 
possible 
Long-term survival possible if 
treatment is effective 
Survival benefit demonstrated 
in well-designed clinical trials 
Orally active 
Disadvantages No standardized treatment 
protocol/regimen 
Uncertain survival benefit 
Very few trials comparing 
HAIC with systemic 
chemotherapy 
Specific skill required for 
administration (e.g., arterial 
catheterization) 
Associated with unique 
complications 
Poor rate of tumour shrinkage 
Restricted to patients with 
preserved liver function 
(Child-Pugh class A liver 
disease) 
May cause serious adverse 
reactions that necessitate 
treatment discontinuation 
Not well utilized in Japan† 
Drug withdrawal criteria not 
yet established 
Tumour response rate 14%–85%[35, 45] 2%–3.7%[50, 54] 
Survival time (months) 2.6–31.8[35, 45] 6.5–15.6[51, 54] 
Cost ¥1,000,000–¥2,000,000 
(including the cost of arterial 
catheterization and port 
implantation) 
¥600,000 per month 
† Although available in Japan since May 2009,[52] sorafenib has only been used in 
approximately 5,000 patients (personal communication May 2010). 
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Hepatic artery infusion chemotherapy (HAIC) allows long-term administration of 
cytotoxic drugs to the liver. In Japan, HAIC has traditionally been used to treat 
patients with advanced hepatocellular carcinoma (HCC) with vascular invasion and/or 
multiple intrahepatic lesions. The most common chemotherapy drugs used for HAIC 
in Japan are 5-fluorouracil and cisplatin. 
Although HAIC is associated with a high rate of response in some studies, it is not 
associated with a survival benefit. Furthermore, HAIC is associated with 
complications that are not observed with systemic chemotherapy, including peptic 
ulcer, arterial occlusion, and port infection. 
Recently, the molecular target drug sorafenib became the standard therapy for 
advanced HCC on the basis of data from two randomized controlled trials. For this 
reason, the position of HAIC in the treatment of advanced HCC in Japan is under 
discussion. Clinical trials must be undertaken to establish standardized protocols and 
regimens for HAIC, and to determine the efficacy of HAIC in comparison with other 
therapies for HCC.  Without evidence from such trials, HAIC may not find an 
established role in the treatment of HCC, and may even fall out of use. 
Recent evidence suggests that HAIC may be useful in combination with molecular 
targeted therapy. This possibility is currently being investigated in a number of 
clinical trials. 
Abstract word count: 210 (word count limit is up to 400–500 words) 




Conventional chemotherapy for advanced hepatocellular carcinoma (HCC) comprises 
systemic chemotherapy (administered intravenously or orally) or hepatic arterial 
infusion chemotherapy (HAIC). Both systemic chemotherapy and HAIC have been 
shown to be effective in patients with advanced HCC in Japan.{Kudo, 2010 #13} 
HAIC allows long-term administration of cytotoxic drugs to the liver through the use 
of an indwelling catheter-port system. Compared with systemic chemotherapy, HAIC 
delivers a higher local drug concentration directly to liver tumours and is associated 
with fewer significant systemic side effects.{Ganeshan, 2008 #11} In the past, 
catheters were placed surgically under general anaesthesia; however, owing to recent 
advances in interventional radiological techniques, it is now possible to insert 
catheter-port systems percutaneously under local anaesthesia.{Ganeshan, 2008 #11} 
In Japan, HCC is a common malignancy,{Ikai, 2004 #14} and is one of the leading 
causes of cancer mortality.{Makuuchi, 2006 #27} HAIC is a treatment for HCC that 
is used primarily in Japan and some other Asian countries, including Korea. Data 
from some studies indicate that HAIC is associated with a high response rate; 
however, treatment response has not been consistent across studies and there is little 
evidence of a survival benefit with HAIC. 
Recently, molecular targeted therapy became a new field of cancer chemotherapy for 
patients with HCC. The introduction of such agents has meant that the role of HAIC 
in patients with advanced HCC is under discussion. The current review discusses the 
current status of HAIC for the treatment of HCC in Japan and the role that this form 
of treatment may play in the future. 
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Current status of chemotherapy for hepatocellular carcinoma in 
Japan 
According to data from the 14th to the 18th Nationwide Follow-up Survey of Primary 
Liver Cancer conducted in Japan between 1996 and 2005,{Ikai, 2005 #15; Ikai, 2007 
#16; Ikai, 2004 #14; Ikai, 2010 #18; Yoshio, 2000 #26} chemotherapy was used as 
initial therapy in 3.4[O4]%[LJS5] of newly diagnosed patients with HCC in 1996–
1997[LJS6][O7], increasing to 5.5% of patients in 2004–2005 (Figure 1A). Of those 
patients who were initially treated with chemotherapy, HAIC was the most common 
administration method (Figure 1B); between 2000 and 2005, the proportion of 
chemotherapy patients who received treatment in the form of HAIC was 
approximately 90%.{Ikai, 2004 #14; Ikai, 2005 #15; Ikai, 2007 #16; Ikai, 2010 #18; 
Yoshio, 2000 #26} In the same time period, the proportion of patients with HCC who 
had a complete response to chemotherapy (assessed according to various criteria) 
ranged from 13.5%–19.9%. During the same time period, 25.5%–30.2% of patients 
had a partial response to chemotherapy (Figure 1C).{Ikai, 2004 #14; Ikai, 2005 #15; 
Ikai, 2007 #16; Ikai, 2010 #18; Yoshio, 2000 #26} 
Guideline recommendations for the use of hepatic artery infusion 
chemotherapy in patients with hepatocellular carcinoma 
Japan 
The Clinical Practice Guidelines for Hepatocellular Carcinoma (J-HCC) were the first 
evidence-based guidelines for the treatment of HCC in Japan. The J-HCC guidelines 
were compiled by an expert panel supported by the Japanese Ministry of Health, 
Labour, and Welfare, and encompass the prevention, diagnosis, surveillance, and 
treatment of HCC. They were first developed in 2005, and were subsequently revised 
in 2009. The most recent version of the J-HCC guidelines recommend the use of 
HAIC (or transcatheter arterial embolization [TACE]) in patients with multifocal 
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HCC (four or more tumours) who have Child-Pugh class A or B liver disease. HAIC 
(or hepatectomy or TACE) is also recommended for those patients with Child-Pugh 
class A liver disease accompanied by vascular invasion.{The Japan Society of 
Hepatology, 2010 #10} An English translation of the guidelines is available at the 
following URL: http://www.jsh.or.jp/english/examination.html. 
Other countries 
Although HAIC is recommended for the treatment of HCC in certain situations in 
Japan, as described previously, a number of international practice guidelines do not 
endorse the use of HAIC in patients with HCC. The Barcelona-Clinic Liver Cancer 
staging classification and treatment schedule{Llovet, 2003 #12} does not include 
HAIC in its list of treatment options for HCC, while the American Association for 
Study of Liver Disease practice guidelines{Bruix, 2010 #4} state that “systemic or 
selective intra-arterial chemotherapy is not recommended and should not be used as 
standard of care”. Although the 2010 version of the practice guidelines for 
hepatobiliary cancers developed by the National Comprehensive Cancer Network 
recommends the use of systemic single-agent or multiple-agent chemotherapy or 
intra-arterial chemotherapy in patients with unresectable HCC, this is restricted to 
those patients participating in a clinical trial.{National Comprehensive Cancer 
Network, 2010 #3} 
Hepatocellular carcinoma versus systemic chemotherapy 
There are almost no well-designed, controlled studies that have directly compared 
systemic chemotherapy and HAIC for the treatment of HCC, and there are insufficient 
data to show that one treatment is better than the other. Indeed, in the 2009 version of 
the J-HCC guidelines it is noted that there is “no sufficient scientific evidence that 
hepatic arterial infusion chemotherapy is more beneficial than systemic 
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chemotherapy”.{The Japan Society of Hepatology, 2010 #5} In developing the 
guidelines, an analysis of response rates in trials that investigated each type of 
chemotherapy in 30 or more patients was undertaken. Data from these trials showed 
that the rate of response was 22%–71% with HAIC compared with 0%–28% with 
single-agent systemic chemotherapy and 2.5%–39% with multiple-agent systemic 
chemotherapy; the median survival time (MST) with these treatment modalities was 
4.4–32.4, 1.9–13.7, and 3.0–30.9 months, respectively.{The Japan Society of 
Hepatology, 2010 #5} These data suggested that HAIC was more beneficial than 
systemic chemotherapy; however, there was great variability in the outcomes assessed, 
most likely as a result of the different sample sizes and selection criteria of the 
individual studies. The final recommendation that HAIC was no better than systemic 
chemotherapy was based on the results of a randomized trial that directly compared 
the effects of doxorubicin administered as HAIC or as systemic chemotherapy in 64 
patients with unresectable HCC.{Tzoracoleftherakis, 1999 #1} Although the 
proportion of patients who experienced a complete response or a partial response was 
numerically higher in the HAIC group versus the systemic chemotherapy group 
(60.0% vs. 44.1% of patients), MST was not significantly different in the two 
treatment groups (7.0 vs. 6.5 months). 
Standard hepatic artery infusion chemotherapy protocols 
In contrast to what has been observed for other malignant tumours, there are relatively 
few large-scale, randomized controlled studies that have investigated the efficacy of 
chemotherapy for the treatment of HCC.{The Japan Society of Hepatology, 2010 #5} 
As such, according to the expert panel that developed the 2009 J-HCC guidelines, 
there is no established standard chemotherapy protocol for the treatment of advanced 
HCC.{The Japan Society of Hepatology, 2010 #5} 
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Within Japan, 5-fluorouracil (5-FU) and cisplatin (CDDP) are the most common 
chemotherapy drugs used for HAIC; these agents account for more than 50% of those 
used for HAIC. [LJS8] [O9]HAIC may involve multiple agents or a single agent. In Japan, 
representative HAIC protocols include 5-FU plus CDDP (primarily at low doses), 
interferon (IFN) plus 5-FU, and CDDP alone; however, the optimal regimens of these 
protocols have not been established. 
Cisplatin plus 5-fluorouracil 
HAIC with low-dose 5-FU plus CDDP is commonly used in patients with advanced 
HCC, but requires careful monitoring of haematological function.{Ueshima, 2010 
#25} In studies involving 16–97 patients[LJS10],[O11]{Ando, 2002 #29; Eun, 2009 #37; 
Lai, 2003 #33; Naganuma, 2007 #36; Okuda, 1999 #28; Park, 2007 #35; Sumie, 2003 
#32; Tanioka, 2003 #30; Ueshima, 2010 #25; Kim, 2010 #39; Cheong, 2005 #34; 
Murata, 2003 #31} HAIC with 5-FU plus CDDP was associated with a complete or 
partial response in 5[LJS12]%[O13]–71% of patients and an MST of 6.0–15.9 months. 
There was much variation in the dose of 5-FU and CDDP administered in these 
studies, as well as variation in the timing and duration of the two treatments. To 
establish the optimum regimen of HAIC with 5-FU plus CDDP, the dose, infusion 
time, and dosing interval of 5-FU as well as the dose, infusion time, and dosing 
duration of CDDP should be standardized in future. Further research should also 
focus on the combination of 5-FU and CDDP with leucovorin/isovorin{Yamasaki, 
2005 #40; Yamasaki, 2003 #41} and lipiodol{Nagamatsu, 2010 #42}; preliminary 
data from small-scale studies show that these combinations may be suitable for 
patients with advanced HCC. 
Interferon plus 5-fluorouracil 
Combination chemotherapy with IFN and 5-FU has been shown to be effective in 
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patients with HCC. In studies involving 10–116 patients with HCC,{Enjoji, 2005 #44; 
Hirooka, 2010 #51; Kuroda, 2007 #47; Nagano, 2007 #48; Obi, 2006 #46; Ota, 2005 
#45; Sakon, 2002 #43; Uka, 2007 #49; Uka, 2007 #50} HAIC with IFN plus 5-FU 
was associated with a response rate of 14%–85[LJS14]%[O15] and an MST of 6.5–31.8 
months. In several of the studies, 5-FU was administered as a continuous infusion at a 
dose of approximately 500 mg/day, whereas the type and the dose of IFN varied. 
Further research should focus on the optimum IFN species (IFNα-2b, natural IFNα, or 
pegylated IFN) to use, the patient groups for which HAIC with IFN plus 5-FU is 
indicated, and the rationale for combining IFN with a cytotoxic drug. In addition, 
research should assess the feasibility of combining IFN, 5-FU and CDDP; although 
data suggest that HAIC with IFN, 5-FU and CDDP may be beneficial in patients with 
HCC,{Baba, 2004 #52} no standard regimen for this combination has been 
established. 
Single-agent cisplatin 
In studies involving 10–84 patients[LJS16],[O17]{Carr, 2000 #53; Chung, 2000 #54; 
Court, 2002 #55; Kajanti, 1986 #56} HAIC with CDDP was associated with response 
rates of 5[LJS18]%[O19]–42% and an MST of 7.1[LJS20]–[O21]10.7 months (mean survival 
time of 19.7 months in one study). Although the first CDDP formulation (fine 
powder) intended for HAIC (IA call®; Nippon Kayaku, Tokyo, Japan) was approved 
and marketed in Japan in 2004, the optimum formulation, dose, and dosing interval of 
this drug has yet to be determined. Further research into the efficacy of CDDP in 
combination with lipiodol should be undertaken; data from a phase I/II study 
conducted in patients with unresectable HCC has shown this combination to be 
effective and well tolerated.{Yamashita, 2009 #58} 
Case studies of patients treated with hepatic artery infusion 




A number of patients with advanced HCC have shown a dramatic response to several 
cycles of HAIC. Such patients were treated with curative therapy, including hepatic 
resection and radiofrequency ablation, following treatment with HAIC and went on to 
survive for more than five years. Two such case studies are described here. Despite 
that the patients showed a dramatic response to HAIC, few prospective studies have 
evaluated the survival of HCC patients following treatment with HAIC. 
A 70-year-old male with type C liver cirrhosis (Child-Pugh score 7/class B) presented 
to the clinic. The patient had multifocal HCC (major lesion, 11 cm) with tumour 
thrombus in the right portal branch (VP3) and leg veins, but had no lymph node or 
distant metastases.  Nine cycles of HAIC with IFN plus 5-FU were administered from 
November 2004, resulting in a 48% reduction in tumour size (partial response). Two 
subsequent cycles of HAIC with IFN, 5-FU, and CDDP were given but further 
tumour regression was not observed. In October 2006, the patient underwent hepatic 
resection as salvage therapy. As of March 2010, the patient was alive and recurrence 
free. Owing to the effect of salvage therapy, the survival time from the start of HAIC 
was more than 65 months. This experience reemphasizes the importance of salvage 
therapy. 
A 60-year-old male with type B liver cirrhosis (Child-Pugh score 8/class B) with 
multifocal HCC (major lesion, 5.3 cm), tumour thrombus in the right to left portal 
branches (VP4), and no lymph node or distant metastases presented for treatment.  
Five cycles of HAIC with IFN plus 5-FU were administered from December 2004 
onwards. A 47% decrease in tumour size was observed, as was regression of portal 
invasion.  Suspected residual tumours were treated by radiofrequency ablation. The 
patient was subsequently treated with three cycles of radio frequency ablation for 
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recurrence in segment 5 and has survived for more than five years.  The survival time 
from the start of HAIC was more than 64 months. 
Complications of hepatic artery infusion chemotherapy 
HAIC requires the precise placement of the catheter tip so as to optimize hepatic 
chemoinfusion and to reduce extrahepatic cytotoxic side effects.{Ganeshan, 2008 
#11} To this end, specific skills for arterial catheterization are required. 
Because HAIC requires the implantation of a catheter-port system, it is considered 
invasive for patients. Furthermore, the process is associated with complications that 
are not observed with systemic chemotherapy, including bruising and formation of 
hematomas at the puncture and port pocket site. Additional complications may 
include dislocation of the catheter, thrombotic occlusion of the catheter and/or the 
hepatic artery, and stroke.{Ganeshan, 2008 #11} Development of abdominal pain 
following HAIC has also been observed by the author. Further investigation with 
gastric endoscopy in the affected patient showed a red lesion with an ulcerated centre 
in the vestibule, suggesting that the cytotoxic drug used for HAIC may have leaked 
into the gastrointestinal tract causing a peptic ulcer. 
Vascular complications of HAIC, including hepatic arterial vasculitis and occlusion, 
port infection, and catheter occlusion, may also occasionally occur. 
Hepatic artery infusion chemotherapy compared with sorafenib 
Within Japan, HAIC is considered an unsuitable treatment in patients with HCC with 
multiple intrahepatic nodules and in patients with HCC with portal invasion, lymph 
node involvement, and/or distant metastasis.  Thus, HAIC is restricted to patients with 
HCC with extensive vascular invasion (VP3/4), patients with HCC with very 
extensive portal invasion (VP4) and a massive intrahepatic lesion, and in patients with 
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bilobar multifocal HCC with multiple intrahepatic lesions that are unresponsive to 
TACE.  
Recently, the role of HAIC for the treatment of advanced HCC in Japan has been 
revisited. This has been prompted by the publication of the results of two randomized 
controlled clinical trials, which showed that the molecular target therapy sorafenib 
was effective for the treatment of advanced HCC.{Llovet, 2008 #20; Cheng, 2009 
#21} The outcomes of these trials has led to sorafenib being preferentially indicated 
for the treatment of HCC with distant metastasis, multiple intrahepatic lesions, and/or 
vascular invasion, thereby, in the author’s opinion, reducing the role of HAIC in the 
treatment of HCC in Japan. If HAIC is to be considered a recognized treatment for 
HCC and not fall out of use, clinical studies that establish its efficacy in comparison 
with other therapies for HCC as well as the optimal treatment protocol and regimen 
should be conducted. 
Sorafenib was approved for use in Japan in May 2009.{Bayer, 2009 #22} A 
comparison of HAIC and sorafenib with regard to regional usage, advantages, 
disadvantages, tumour response rate, patient survival and cost of treatment is shown 
in Table 1. 
Sequential therapy with sorafenib and hepatic artery infusion 
chemotherapy 
It is the author’s experience that sequential therapy with sorafenib then HAIC may be 
effective. Treatment with sorafenib then HAIC was trialled in a 70-year-old male with 
type C liver cirrhosis diagnosed with HCC in April 2009 and referred to the author’s 
clinic in May 2009.  The patient was an alcoholic and had a family history of HCC.  
Computed tomography (CT) and CT hepatic arteriography showed bilobar multifocal 
HCC with multiple intrahepatic lesions.  At baseline the patient had Child-Pugh 
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class A liver disease. The patient was treated with sorafenib 800 mg/day but 
experienced fever, rash and back pain. Further investigation showed that the back pain 
was the result of bone metastasis that was not present at the initial diagnosis.  The 
response to sorafenib was judged as progressive disease and radiotherapy was 
directed toward the bone metastasis. The patient then received two cycles of HAIC 
with IFN, 5-FU, and CDDP and the liver tumour size was reduced by 34% (partial 
response according to version 1 of the Response Evaluation Criteria In Solid Tumors 
{Therasse, 2000 #23}) (Figure 2). The patient remains alive 13 months after the start 
of sorafenib therapy. This case study is intriguing as it highlights the possibility that 
prior treatment with sorafenib may render tumour cells more sensitive to cytotoxic 
effects. Further experience with HAIC in other patients unresponsive to sorafenib also 
suggests prior treatment with sorafenib may enhance tumour response to cytotoxic 
drugs. 
Concurrent treatment with HAIC and sorafenib is now under investigation in several 
clinical trials in Japan, including the Phase III SILIUS trial (clinicaltrials.gov 
identifier, NCT01214343[LJS22][Y23]; UMIN clinical trials registry identifier, 
UMIN000004315). This randomized, open-label trial will compare the efficacy of 28-
day cycles of sorafenib alone (400 mg twice daily) and sorafenib plus HAIC 
comprising low-dose CDDP (20 mg/m2 on days 1 and 8), and 5-FU (330 mg/m2 
administered continuously on days 1–5 and days 8–12) in 190 patients with advanced 
HCC aged >20 years. Treatment will be continued until radiographic or symptomatic 
progression or the development of unacceptable toxicity. The primary outcome of the 
trial is overall survival, but time to disease progression, progression-free survival, 
change in tumour markers, and biomarkers predicting efficacy will also be evaluated. 
The start date of the trial was October 2010, and the estimated completion date is 
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September 2013. As of January 2011, recruitment into the trial was ongoing. 
The safety of sorafenib and CDDP HAIC is also being investigated in a Phase I, non-
randomized, dose-finding clinical trial in patients with advanced HCC (UMIN clinical 
trials registry identifier, UMIN000001496). Twenty-one patients aged between 20 and 
79 years will receive sorafenib 400 mg twice daily combined with six courses of 
CDDP administered every 4–6 weeks. The date of first enrolment into the study was 
December 2010. 
Conclusions 
Traditionally, HAIC has been used in Japan to treat HCC with vascular invasion 
and/or multiple intrahepatic lesions. Although HAIC has been associated with high 
response rates in some studies, the outcome of therapy has not been consistent. 
Furthermore, there is little evidence of a survival benefit with HAIC. Sorafenib, a 
molecular target drug, has been established as the new standard of care in patients 
with HCC, based upon the results of two randomized controlled clinical trials. As 
such, the position of HAIC for the treatment of advanced HCC is under discussion. If 
HAIC is to be considered a recognized treatment for HCC, clinical studies that 
establish its efficacy in comparison with other therapies for HCC as well as the 
optimal treatment protocol and regimen must be undertaken. In the absence of such 
data, HAIC may fall out of use. Recently, it has emerged that HAIC may be useful 
when combined (either sequentially or concurrently) with sorafenib. The combination 
of HAIC with molecular targeted therapy is currently being investigated in a number 
of clinical trials, the results of which are awaited with interest. 
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Table 1. [LJS24]Key characteristics of hepatic artery infusion chemotherapy (HAIC) 
and sorafenib for the treatment of hepatocellular carcinoma. 
 HAIC Sorafenib 
Primary country of use Japan and Korea USA, Europe 
Advantages Substantial tumour shrinkage 
possible 
Regression of tumour thrombi 
possible 
Long-term survival possible if 
treatment is effective 
Survival benefit demonstrated 
in well-designed clinical trials 
Orally active 
Disadvantages No standardized treatment 
protocol/regimen 
Uncertain survival benefit 
Very few trials comparing 
HAIC with systemic 
chemotherapy 
Specific skill required for 
administration (e.g., arterial 
catheterization) 
Associated with unique 
complications 
Poor rate of tumour shrinkage 
Restricted to patients with 
preserved liver function 
(Child-Pugh class A liver 
disease) 
May cause serious adverse 
reactions that necessitate 
treatment discontinuation 
Not well utilized in Japan† 
Drug withdrawal criteria not 
yet established 
Tumour response rate 0[LJS25]%[O26]–85% 2%–11[LJS27]%[O28] 
Survival time (months) 1.6[LJS29]–[O30]31.8 6.5–15.6[LJS31][O32] 
Cost ¥10,000,000–¥20,000,000 
[O33](including the cost of 
arterial catheterization and port 
implantation) 
¥600,000 per month[LJS34] 
† Although available in Japan since May 2009,{Bayer, 2009 #22} sorafenib has only been 
used in approximately 5,000 patients (personal communication[LJS35])[O36]. 




Figure 1A. [LJS37]T[LJS38][O39]reatment modality in newly diagnosed patients with 
hepatocellular carcinoma from 1996 to 2005 according to data from the 14th to 18th 
Nationwide Follow-up Survey of Primary Liver Cancer in Japan.{Ikai, 2004 #14; Ikai, 
2005 #15; Ikai, 2007 #16; Ikai, 2010 #18; Yoshio, 2000 #26} TACE = transcatheter 
arterial embolization. 



















Figure 1B.[LJS40] [LJS41]M[O42]ethod of chemotherapy administration in newly diagnosed 
patients with hepatocellular carcinoma from 1996 to 2005 according to data from the 
14th to the 18th Nationwide Follow-up Survey of Primary Liver Cancer in Japan.{Ikai, 
2004 #14; Ikai, 2005 #15; Ikai, 2007 #16; Ikai, 2010 #18; Yoshio, 2000 #26} HAIC = 
hepatic arterial infusion chemotherapy. 
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Figure 1C. [LJS43]Response rates to chemotherapy for newly diagnosed patients with 
hepatocellular carcinoma from 1996 to 2005 according to data from the 14th to the 
18th Nationwide Follow-up Survey of Primary Liver Cancer in Japan.{Ikai, 2004 #14; 
Ikai, 2005 #15; Ikai, 2007 #16; Ikai, 2010 #18; Yoshio, 2000 #26}[LJS44][O45] 
















Figure 2. Computed tomography images (a) before [LJS46][O47]and (b) after treatment 
with sorafenib followed sequentially by hepatic artery infusion chemotherapy 
comprising 5-fluorouracil, cisplatin, and interferon in a 70-year-old male with type C 
liver cirrhosis diagnosed with hepatocellular carcinoma.[LJS48][O49] 
 
